Kim Daejin, Hoory Talia, Monie Archana, Ting Jenny Pan-Yun, Hung Chien-Fu, Wu T-C
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
J Immunol. 2008 May 15;180(10):7019-27. doi: 10.4049/jimmunol.180.10.7019.
Administration of DNA vaccines via gene gun has emerged as an important form of Ag-specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression and also induces expression of class I molecules. We reasoned that the gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve MHC I and II processing could enhance DNA vaccine potency. We observed that DC-1 cells transfected with CIITA DNA lead to higher expression of MHC I and II molecules, leading to enhanced Ag presentation through the MHC I/II pathways. Furthermore, our data suggested that coadministration of DNA-encoding calreticulin (CRT) linked to human papillomavirus (HPV) 16 E6 Ag (CRT/E6) with CIITA DNA leads to enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. In addition, coadministration of the combination of CRT/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive epitope (Ii-PADRE) further enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. Treatment with the combination vaccine was also shown to enhance the antitumor effects and to prolong survival in TC-1 tumor-bearing mice. Vaccination with the combination vaccine also led to enhanced E6-specific CD8(+) memory T cells and to long-term protection against TC-1 tumors and prolonged survival in vaccinated mice. Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting.
通过基因枪接种DNA疫苗已成为一种重要的抗原特异性免疫疗法。MHC CIITA是MHC II类表达的主要调节因子,也能诱导I类分子的表达。我们推测,用基因枪接种CIITA DNA与采用不同策略改善MHC I和II加工的DNA疫苗相结合,可能会增强DNA疫苗的效力。我们观察到,用CIITA DNA转染的DC-1细胞导致MHC I和II分子的表达更高,从而通过MHC I/II途径增强抗原呈递。此外,我们的数据表明,将与人类乳头瘤病毒(HPV)16 E6抗原(CRT/E6)相连的编码钙网蛋白(CRT)的DNA与CIITA DNA共同接种,可增强接种疫苗小鼠中E6特异性CD8(+) T细胞免疫反应。此外,将CRT/E6 DNA与CIITA DNA以及与泛HLA-DR反应性表位(Ii-PADRE)相连的编码恒定链(Ii)的DNA联合接种,进一步增强了接种疫苗小鼠中E6特异性CD8(+) T细胞免疫反应。联合疫苗治疗还显示可增强抗肿瘤作用,并延长携带TC-1肿瘤小鼠的生存期。接种联合疫苗还导致E6特异性CD8(+) 记忆T细胞增加,并对TC-1肿瘤提供长期保护,延长接种疫苗小鼠的生存期。因此,我们的研究结果表明,CIITA DNA与CRT/E6和Ii-PADRE DNA疫苗联合使用是临床上对抗肿瘤的一种潜在有效手段。